← argenx SE (ARGX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
argenx SE (ARGX)
Biological Products, (No Diagnostic Substances) · market cap $58.8B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-29 (est.)
Earnings
Pipeline
17
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
argenx SE (ARGX) is a Belgian immunology-focused biotech with a $56.5B market cap and 1,599 employees, built around efgartigimod — an FcRn antagonist platform — and a multi-asset pipeline spanning neurology, dermatology, and rare autoimmune diseases. The company has multiple Phase 3 programs with high-importance readouts clustered over the next 6–18 months, making it one of the densest near-term catalyst schedules among large-cap biotechs.
The catalyst path
- 2026-10-29 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 2 · Efgartigimod Alfaimp 7/10
- 2027-01-03PDUFA · Efgartigimodimp 9/10
- 2027-01-06 (est.)Phase 3 · efgartigimod administrationimp 9/10
- 2027-03-15 (est.)Phase 3 · Efgartigimod IVimp 9/10
- 2027-04-30 (est.)Phase 2 · Efgartigimod PH20 SCimp 7/10
- 2027-07-15 (est.)Phase 3 · Efgartigimod PH20 SCimp 9/10
- 2027-09-15 (est.)Phase 3 · empasiprubartimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Efgartigimod IV | Phase 3 | Generalized Myasthenia Gravis |
| ARGX-113 | Phase 3 | Pemphigus Vulgaris |
| Efgartigimod PH20 SC | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
| EFG PH20 SC | Phase 3 | Active Idiopathic Inflammatory Myopathy |
| IVIG (Intravenous Immunoglobulin) | Phase 3 | Multifocal Motor Neuropathy (MMN) |
| Efgartigimod | Phase 3 | Postural Orthostatic Tachycardia Syndrome |
| empasiprubart | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy |
| efgartigimod PH20 SC in stage B | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
| ARGX-119 | Phase 2 | Amyotrophic Lateral Sclerosis |
| ARGX-117 | Phase 2 | Multifocal Motor Neuropathy |
| Empasiprubart IV | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy |
| ARGX-119 IV | Phase 2 | Spinal Muscular Atrophy (SMA) |
| ARGX-110 | Phase 2 | Leukemia, Myeloid, Acute |
| efgartigimod administration | Phase 3 | Myasthaenia Gravis |
| Efgartigimod Alfa | Phase 2 | Optic Neuritis |
| Cusatuzumab | Phase 2 | Leukemia, Myeloid, Acute |
| Efgartigimod PH20 (ARGX-113) SC | Phase 2 | Autoimmune Encephalitis (AE) |
Price & technical context
3-month
-0.4%
6-month
+26.0%
12-month
+26.9%
52-wk range
$663.93–$1058.90
vs 50-day MA
-2.2%
vs 200-day MA
+10.0%
Realized vol
33.9%
Max drawdown
-28.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ARGX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 17 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.